

HÃ¥kon Reikvam

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/210249/publications.pdf](https://exaly.com/author-pdf/210249/publications.pdf)

Version: 2025-02-01

144

PR articles

2,535

PR citations

151392

28

PR h-index

172576

48

g-index

155

documents

2783

doc citations

150343

30

h-index

3793

citing authors

#	ARTICLE	IF	PR CITATIONS
1	The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae. <i>Translational Oncology</i> , 2024, 40, 101876.	3.7	5
2	Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations. <i>International Journal of Molecular Sciences</i> , 2024, 25, 5080.	4.5	3
3	A woman in her thirties with dyspnoea two weeks after abdominoplasty. <i>Tidsskrift for Den Norske Laegeforening</i> , 2024, , .	0.1	1
4	Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies. <i>International Journal of Molecular Sciences</i> , 2024, 25, 6356.	4.5	13
5	The prognostic impact of C-reactive protein and albumin in patients diagnosed with acute myeloid leukaemia. <i>EJHaem</i> , 2024, 5, 1223-1235.	1.7	0
6	Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles. <i>Metabolites</i> , 2023, 13, 52.	3.5	6
7	Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis. <i>Biomolecules</i> , 2023, 13, 223.	4.4	7
8	VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia. <i>Case Reports in Hematology</i> , 2023, 2023, 1-7.	0.4	6
9	Better and safer allogeneic stem cell transplantation. <i>Tidsskrift for Den Norske Laegeforening</i> , 2023, , .	0.1	0
10	Pretransplant systemic metabolic profiles in allogeneic hematopoietic stem cell transplant recipients - identification of patient subsets with increased transplant-related mortality. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 375.e1-375.e14.	2.0	8
11	The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients. <i>Cells</i> , 2023, 12, 1003.	4.8	26
12	Platelets for advanced drug delivery in cancer. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 673-688.	5.1	12
13	Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia. <i>Cancers</i> , 2023, 15, 3711.	4.0	12
14	Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis: A Review of Current Literature. <i>Journal of Clinical Medicine</i> , 2023, 12, 5366.	2.6	23
15	Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity. <i>Journal of Clinical Medicine</i> , 2023, 12, 5546.	2.6	8
16	Iron Status and Physical Performance in Athletes. <i>Life</i> , 2023, 13, 2007.	2.8	33
17	En mann i 40-Ã¥rene med transfusjonskrevende anemi. <i>Tidsskrift for Den Norske Laegeforening</i> , 2023, , .	0.1	0
18	Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature. <i>Current Oncology</i> , 2023, 30, 10007-10018.	3.1	3

#	ARTICLE	IF	PR CITATIONS
19	Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. <i>Molecules</i> , 2022, 27, 735.	4.3	21
20	An Abrupt Transition to Digital Teaching—Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown. <i>Healthcare (Switzerland)</i> , 2022, 10, 170.	2.3	6
21	Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 706.	2.6	22
22	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. <i>Biomolecules</i> , 2022, 12, 492.	4.4	4
23	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. <i>Current Oncology</i> , 2022, 29, 2193-2198.	3.1	2
24	MicroRNA serum profiles and chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 5295-5306.	5.1	15
25	Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	19
26	NÅr blodet flyter langsomt. <i>Tidsskrift for Den Norske Laegeforening</i> , 2022, , .	0.1	0
27	Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. <i>Cancers</i> , 2022, 14, 2910.	4.0	5
28	NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition. <i>Biomedicines</i> , 2022, 10, 1881.	3.5	5
29	Eksamensformer i de norske medisinstudiene. <i>Tidsskrift for Den Norske Laegeforening</i> , 2022, , .	0.1	0
30	Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Case Reports in Immunology</i> , 2022, 2022, 1-4.	1.2	1
31	Musculoskeletal Chronic Graft versus Host Disease—A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. <i>Current Oncology</i> , 2022, 29, 8415-8430.	3.1	5
32	Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14706.	4.5	5
33	Trombocytopeni hos kritisk syke pasienter. <i>Tidsskrift for Den Norske Laegeforening</i> , 2021, , .	0.1	0
34	Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. <i>Case Reports in Critical Care</i> , 2021, 2021, 1-6.	0.5	2
35	Carbapenem-Resistant Enterobacteriaceae—Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies. <i>Antibiotics</i> , 2021, 10, 322.	4.3	5
36	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. <i>Cells</i> , 2021, 10, 833.	4.8	6

#	ARTICLE	IF	PR CITATIONS
37	Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1834.	2.6	16
38	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. <i>Cancers</i> , 2021, 13, 2143.	4.0	11
39	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. <i>Cancers</i> , 2021, 13, 1870.	4.0	24
40	Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. <i>Pharmaceuticals</i> , 2021, 14, 423.	4.4	7
41	Hyperferritinemia—A Clinical Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 2008.	2.6	102
42	Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. <i>Clinics and Practice</i> , 2021, 11, 459-466.	2.2	1
43	HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis. <i>Genes</i> , 2021, 12, 1162.	2.6	8
44	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. <i>Journal of Personalized Medicine</i> , 2021, 11, 779.	2.6	19
45	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. <i>Hemato</i> , 2021, 2, 607-627.	1.0	4
46	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. <i>SAGE Open Medical Case Reports</i> , 2021, 9, .	0.5	0
47	Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 74.	2.8	7
48	Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. <i>Journal of Clinical Medicine</i> , 2021, 10, 5190.	2.6	51
49	En ung kvinne med pustevansker og proteinuri. <i>Tidsskrift for Den Norske Laegeforening</i> , 2021, , .	0.1	0
50	Leukemia cutis. <i>Tidsskrift for Den Norske Laegeforening</i> , 2021, , .	0.1	0
51	FEBRILE NEUTROPENIA IN ACUTE LEUKEMIA. EPIDEMIOLOGY, ETIOLOGY, PATHOPHYSIOLOGY AND TREATMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020009.	0.8	73
52	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. <i>Cells</i> , 2020, 9, 1677.	4.8	20
53	Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2020, 1, 102-110.	0.5	0
54	Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, .	0.9	14

#	ARTICLE	IF	PR CITATIONS
55	Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy. Case Reports in Anesthesiology, 2020, 2020, 1-5.	0.4	1
56	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. Cells, 2020, 9, 1155.	4.8	33
57	Critical Upper Airway Obstruction as the First Symptom of Acute Myeloid Leukemia—An Anesthesiologic Reminder. Clinics and Practice, 2020, 10, 1214.	2.2	3
58	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment. Case Reports in Hematology, 2020, 2020, 1-6.	0.4	2
59	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences, 2020, 21, 2907.	4.5	280
60	A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. Journal of International Medical Research, 2020, 48, .	1.4	5
61	Covid-19 og venås tromboembolisme — profylakse og behandling. Tidsskrift for Den Norske Lægeforening, 2020, , .	0.1	0
62	Hyperferritinemi-katarakt-syndrom. Tidsskrift for Den Norske Lægeforening, 2020, , .	0.1	0
63	Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development, 2019, 4, 263-274.	0.9	2
64	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. Journal of Clinical Medicine, 2019, 8, 970.	2.6	27
65	Mondor's disease after extensive training with Nordic walking. Oxford Medical Case Reports, 2019, , .	0.5	2
66	Trisomy 8 in acute myeloid leukemia. Expert Review of Hematology, 2019, 12, 947-958.	2.0	44
67	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy, 2019, 4, .	43.9	64
68	Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs, 2019, 28, 411-420.	4.0	16
69	En mann i 70-årene med ryggsmarter, mageplager og utslett. Tidsskrift for Den Norske Lægeforening, 2019, , .	0.1	0
70	Behandling av akutt myelogen leukemi hos eldre. Tidsskrift for Den Norske Lægeforening, 2019, , .	0.1	0
71	En kvinne i 40-årene med bekkensmerter og uklare MR-funn. Tidsskrift for Den Norske Lægeforening, 2019, , .	0.1	0
72	Severe Nephritis as Initial Sign of Waldenström's Macroglobulinemia. Clinics and Practice, 2019, 9, 127-132.	2.2	0

#	ARTICLE	IF	PR CITATIONS
73	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2018, 27, 377-387.	4.0	37
74	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy, 2018, 20, 740-754.	2.0	5
75	Successful eradication of leptomeningeal plasma cell disease. Oxford Medical Case Reports, 2018, 2018, .	0.5	2
76	Chronic Myeloid Leukemia Relapsing 25 Years after Allogeneic Stem Cell Transplantation. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	3
77	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. Cancers, 2018, 10, 332.	4.0	35
78	Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sanguinis, 2018, 113, 657-668.	1.1	8
79	Myeloid Sarcoma after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. Case Reports in Oncological Medicine, 2018, 2018, 1-5.	0.4	6
80	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. Frontiers in Immunology, 2018, 8, .	5.1	21
81	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. Frontiers in Medicine, 2018, 5, .	2.6	58
82	The Possible Importance of Î²3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 251.	4.5	46
83	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. International Journal of Molecular Sciences, 2018, 19, 382.	4.5	24
84	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opinion on Therapeutic Targets, 2018, 22, 639-653.	3.9	16
85	GelatinÃs benmarg. Tidsskrift for Den Norske Laegeforening, 2018, , .	0.1	0
86	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Review of Clinical Immunology, 2017, 13, 553-569.	3.7	28
87	Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert Opinion on Therapeutic Targets, 2017, 21, 357-369.	3.9	27
88	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia â€“ the biological background for possible strategies. Expert Opinion on Drug Discovery, 2017, 12, 1053-1065.	4.5	34
89	Microcirculation and red cell transfusion in patients with sepsis. Transfusion and Apheresis Science, 2017, 56, 900-905.	1.0	16
90	Non-curative surgery for aortoenteric fistula. Journal of Surgical Case Reports, 2017, 2017, .	0.5	6

#	ARTICLE	IF	PR CITATIONS
91	CDC25 Inhibition in Acute Myeloid Leukemia—A Study of Patient Heterogeneity and the Effects of Different Inhibitors. <i>Molecules</i> , 2017, 22, 446.	4.3	12
92	Altered Immune Activation and IL-23 Signaling in Response to <i>Candida albicans</i> in Autoimmune Polyendocrine Syndrome Type 1. <i>Frontiers in Immunology</i> , 2017, 8, .	5.1	14
93	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia — identification of responders by gene expression profiling of pretreatment leukemic cells. <i>BMC Cancer</i> , 2017, 17, .	3.1	23
94	Ei ung kvinne med brystmerter og dyspn�. <i>Tidsskrift for Den Norske L�egef�orening</i> , 2017, , .	0.1	0
95	Ringsideroblaster. <i>Tidsskrift for Den Norske L�egef�orening</i> , 2017, , .	0.1	0
96	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. <i>Frontiers in Immunology</i> , 2016, 7, .	5.1	27
97	Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1823.	4.5	36
98	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 373-387.	1.1	3
99	Dysmorfe plasmaceller i blod. <i>Tidsskrift for Den Norske L�egef�orening</i> , 2016, 136, 1650-1650.	0.1	1
100	Myeloproliferative neoplasier og JAK2-mutasjonar. <i>Tidsskrift for Den Norske L�egef�orening</i> , 2016, 136, 1889-1894.	0.1	2
101	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3995-3995.	4.2	1
102	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. <i>Oncotarget</i> , 2015, 6, 2794-2811.	1.7	15
103	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. <i>Stem Cell Research</i> , 2015, 15, 530-541.	0.6	56
104	The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers — a comparative study of serum versus plasma samples. <i>Journal of Immunological Methods</i> , 2015, 418, 19-28.	1.5	22
105	Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. <i>Thrombosis Research</i> , 2015, 136, 30-39.	2.4	47
106	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) — gene transcription, cell cycle regulation, metabolism and intercellular communication. <i>Expert Review of Hematology</i> , 2015, 8, 299-313.	2.0	14
107	Effects of cytarabine on activation of human T cells — cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, .	2.7	27
108	Emerging therapeutic targets in human acute myeloid leukemia (part 2) — bromodomain inhibition should be considered as a possible strategy for various patient subsets. <i>Expert Review of Hematology</i> , 2015, 8, 315-327.	2.0	9

#	ARTICLE	IF	PR CITATIONS
109	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. <i>Metabolomics</i> , 2015, 12, .	2.8	37
110	Nutrition in Allogeneic Stem Cell Transplantation - Clinical Guidelines and Immunobiological Aspects. <i>Current Pharmaceutical Biotechnology</i> , 2015, 17, 92-104.	2.3	9
111	Plasmaceller med inklusjonar. <i>Tidsskrift for Den Norske Laegeforening</i> , 2015, 135, 1957-1957.	0.1	1
112	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. <i>Blood</i> , 2015, 126, 4931-4931.	4.2	0
113	Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	1.7	16
114	Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia – The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms. <i>Molecules</i> , 2014, 19, 18414-18447.	4.3	78
115	Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. <i>Transfusion and Apheresis Science</i> , 2014, 51, 97-102.	1.0	30
116	Antileukaemic effect of PI3K/PTEN/mTOR inhibitors in acute myeloid leukaemia – gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. <i>British Journal of Haematology</i> , 2014, 164, 200-211.	2.4	37
117	Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. <i>SpringerPlus</i> , 2014, 3, .	1.5	23
118	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1237-1251.	3.9	25
119	Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 757-777.	4.7	35
120	Heat shock protein 70 – the next chaperone to target in the treatment of human acute myelogenous leukemia?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 929-944.	3.9	6
121	Akutt promyelocytyleukemi. <i>Tidsskrift for Den Norske Laegeforening</i> , 2014, 134, 1052-1055.	0.1	2
122	The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine – The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation. <i>Toxins</i> , 2013, 5, 336-362.	3.9	32
123	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 551-563.	4.0	29
124	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	2.5	10
125	Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. <i>Oncotarget</i> , 2013, 4, 830-843.	1.7	44
126	Tidleg trombocyttransfusjon ved akutt leukemi er best. <i>Tidsskrift for Den Norske Laegeforening</i> , 2013, 133, 629-629.	0.1	0

#	ARTICLE	IF	PR CITATIONS
127	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. <i>Blood</i> , 2013, 122, 2625-2625.	4.2	1
128	The angioregulatory cytokine network in human acute myeloid leukemia – from leukemogenesis via remission induction to stem cell transplantation. <i>European Cytokine Network</i> , 2012, 23, 140-153.	1.2	46
129	The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. <i>Platelets</i> , 2012, 23, 299-308.	2.5	18
130	The Pretransplantation Serum Cytokine Profile in Allogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 190-199.	1.6	36
131	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. <i>European Journal of Haematology</i> , 2012, 89, 478-490.	1.9	21
132	Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 587-603.	4.0	25
133	Questionnaire-Related Deferrals in Regular Blood Donors in Norway. <i>Journal of Blood Transfusion</i> , 2012, 2012, 1-4.	1.0	6
134	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status – consequences and potentials for pharmacological intervention. <i>British Journal of Haematology</i> , 2012, 156, 468-480.	2.4	39
135	Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. <i>American Journal of Hematology</i> , 2012, 87, 368-376.	6.1	37
136	En mann med smerter etter kneoperasjon. <i>Tidsskrift for Den Norske Laegeforening</i> , 2012, 132, 1472-1474.	0.1	0
137	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. <i>European Cytokine Network</i> , 2011, 22, 52-62.	1.2	17
138	Untangling the intracellular signalling network in cancer – A strategy for data integration in acute myeloid leukaemia. <i>Journal of Proteomics</i> , 2011, 74, 269-281.	2.4	6
139	Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications. <i>BioMed Research International</i> , 2011, 2011, .	2.5	77
140	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. <i>European Journal of Haematology</i> , 2010, 84, 239-251.	1.9	54
141	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 169-183.	4.0	40
142	Thrombelastography. <i>Transfusion and Apheresis Science</i> , 2009, 40, 119-123.	1.0	143
143	Nuclear Factor- κ B Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. <i>Critical Reviews in Oncogenesis</i> , 2009, 15, 1-41.	0.9	48
144	Granulocyttransfusjon. <i>Tidsskrift for Den Norske Laegeforening</i> , 2009, 129, 416-419.	0.1	1